This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

New Treatments for Unstable Angina and Non–Q-Wave Myocardial Infarction

Jeffrey I. Weitz, MD; Shannon M. Bates, MD

Arch Intern Med. 2000;160:749-758.

The goals of therapy for unstable angina and non–Q-wave myocardial infarction (MI) are to maintain myocardial perfusion by inhibiting platelet aggregation and fibrin deposition at sites of plaque rupture, thereby preventing ongoing or new myocardial ischemia and cardiac death. Although aspirin and heparin sodium are cornerstones in the management of unstable angina and non–Q-wave MI, both have significant limitations that have prompted the development of new agents. The thienopyridines, ticlopidine hydrochloride and clopidogrel, appear to be at least as effective as aspirin in the management of unstable angina. Glycoprotein IIb/IIIa receptor antagonists are a new class of platelet inhibitors that are more potent than aspirin, because they target the final common pathway of platelet aggregation. Low-molecular-weight heparins provide a more stable pharmacodynamic response and are more convenient to use than unfractionated heparin. Direct thrombin inhibitors show promise for inhibiting thrombin-mediated platelet aggregation and fibrin deposition. We focus on the opportunities presented by these agents, detailing mechanisms of action, advantages over aspirin and heparin, and performance in recent clinical trials.

From the Department of Medicine, McMaster University (Drs Weitz and Bates), and Hamilton Civic Hospitals Research Centre (Dr Weitz), Hamilton, Ontario. Dr Weitz is a paid consultant for The Medicines Company, Boston, Mass, and has been a paid speaker for Sanofi, Paris, France; Rhone Poulence Rorer, Collegeville, Pa; Pharmacia & Upjohn, Peapack, NJ; and Merck Frosst, Montreal, Quebec.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(6):873-874.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bivalirudin Use in Carotid Endarterectomy in a Patient with Heparin-Induced Thrombocytopenia
Finks
The Annals of Pharmacotherapy 2006;40:340-343.
ABSTRACT | FULL TEXT  

The Myth of the Non-Q-Wave Myocardial Infarction
Phibbs
Arch Intern Med 2000;160:3169-3169.
FULL TEXT  

Dalteparin for Unstable Angina and Non-Q-Wave Myocardial Infarction
Borja et al.
Arch Intern Med 2000;160:3169-3170.
FULL TEXT